Please use this identifier to cite or link to this item: https://doi.org/10.1177/1470320313510584
Title: Aliskiren and losartan trial in non-diabetic chronic kidney disease
Authors: Woo, Keng-Thye
Choong, Hui-Lin
Wong, Kok-Seng 
Tan, Han-Kim
Foo, Marjorie
Fook-Chong, Stephanie 
Lee, Evan JC 
Anantharaman, Vathsala 
Lee, Grace SL
Chan, Choong-Meng 
Keywords: Science & Technology
Life Sciences & Biomedicine
Peripheral Vascular Disease
Cardiovascular System & Cardiology
Aliskiren
chronic kidney disease
proteinuria
side effects
clinical trial
ANGIOTENSIN RECEPTOR BLOCKERS
DIRECT RENIN INHIBITOR
EFFICACY
SAFETY
METAANALYSIS
HYPERTENSION
MANAGEMENT
RAMIPRIL
Issue Date: 1-Dec-2014
Publisher: SAGE PUBLICATIONS LTD
Citation: Woo, Keng-Thye, Choong, Hui-Lin, Wong, Kok-Seng, Tan, Han-Kim, Foo, Marjorie, Fook-Chong, Stephanie, Lee, Evan JC, Anantharaman, Vathsala, Lee, Grace SL, Chan, Choong-Meng (2014-12-01). Aliskiren and losartan trial in non-diabetic chronic kidney disease. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 15 (4) : 515-522. ScholarBank@NUS Repository. https://doi.org/10.1177/1470320313510584
Abstract: Introduction: This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angiotensin II receptor blocker (ARB)) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease (CKD) over a 3-year period. Materials and methods: This was a randomised trial in 155 patients with non-diabetic CKD comparing aliskiren (150 mg/day) (n=52) versus losartan (100 mg/day) (n=52) and the third group aliskiren (150 mg/day) combined with losartan (100 mg/day) (n=51). The trial utilised primary renal end points of eGFR <15 ml/min or end-stage renal failure. Results: All three groups had significant reduction of proteinuria (p<0.001 for all). The changes in eGFR, total urinary protein from baseline to each year were not significantly different between the three therapeutic groups. Conclusion: This study in non-diabetic CKD patients showed that combination therapy with aliskiren and ARB was as efficacious as aliskiren alone and ARB alone. There was one patient who developed a non-fatal stroke in the combined aliskiren and ARB group while the other two groups had none.
Source Title: JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
URI: https://scholarbank.nus.edu.sg/handle/10635/229319
ISSN: 14703203
17528976
DOI: 10.1177/1470320313510584
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Aliskiren and Losartan in NonDiabetic Kideny Disease.pdf192.3 kBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

9
checked on Oct 1, 2022

Page view(s)

29
checked on Sep 29, 2022

Download(s)

1
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.